| Metric | Q3 2026 | Q3 2025 |
|---|---|---|
| Revenue | 10.0 | — |
| Profit before tax | -108.9 | -51.5 |
| Net income | -108.9 | -51.5 |
| EPS (diluted, $ a share) | $-1.65 | $-1.22 |
A dash means the filing did not report that period. Growth is not shown when either period was a loss. Figures from the filing's XBRL data.
10-Q filed with the SEC, NASDAQ: ZBIO. Figures from the filing's XBRL data; summary written with AI assistance from the filing.
Zenas BioPharma, Inc.: key numbers
- Share price
- $27.93Close, Nov 16
- Market cap
- $1.89B
- Shares outstanding
- 67.82MLatest SEC cover page
- Sector
- Life Sciences
- Industry
- Pharmaceutical PreparationsSIC 2834
Today's reference numbers, updated daily. Not a valuation or a recommendation.
More from Zenas BioPharma, Inc.
All →Zenas BioPharma Capital Raise
Zenas BioPharma filed a new prospectus supplement to increase its at-the-market (ATM) offering program capacity by $200 million. This replaces a prior supplement under which the company had already sold approximately $153.2 million in common stock, leaving $46.8 million unsold from the previous authorization.
- Counterparty
- Jefferies LLC
Zenas BioPharma Financial Results
Zenas BioPharma reported third quarter 2026 financial results and provided a corporate update, highlighting the FDA's acceptance of its BLA for obexelimab with a PDUFA date of May 27, 2027. The company ended the quarter with $647.1 million in cash and investments, which it expects will fund operations into 2027 as it prepares for potential commercialization.
- Term
- Q3 2026
“This quarter we continued to execute across our portfolio as we prepare for the potential commercialization of obexelimab for the treatment of IgG4-RD. Following the FDA’s acceptance of our BLA in the second quarter of this year, and the recent submission of our MAA to the EMA, we remain focused on commercial readiness ahead of the potential launch.”
Lonnie Moulder, Founder and Chief Executive Officer
“Across our broader pipeline, we remain on track to report topline Phase 2 SunStone data in SLE and initial Phase 1 data for our oral IL-17 inhibitor, ZB021, this quarter. We look forward to closing out a very productive year as we turn our attention to 2027 and continue to build toward our vision of becoming a fully integrated, global development and commercial-stage biopharmaceutical company.”
Lonnie Moulder, Founder and Chief Executive Officer
Zenas BioPharma Clinical Trial Data
Zenas BioPharma announced new data from its Phase 3 INDIGO trial and open-label extension for obexelimab in patients with IgG4-related disease (IgG4-RD). The findings demonstrated sustained clinical activity with a 93% probability of remaining flare-free over 12 months and a significant reduction in cumulative glucocorticoid toxicity compared to placebo.